NAD+ and peptides for ADHD and energy: what the science says

What's this video probably claiming?

Based on the hashtag combination of #nad, #energy, #adhd, and #peptide, this video is almost certainly pitching NAD+ (nicotinamide adenine dinucleotide) as a therapeutic tool for ADHD symptoms and fatigue, possibly alongside peptides like semax or selank, which are the compounds most associated with cognitive and attention-related claims in peptide communities. The creator likely frames NAD+ as a cellular energy booster that addresses the neurological root of ADHD, rather than just a supplement. The "link in bio" format is a reliable signal that a product or consultation service is being sold. The hashtag #peptideeducation is frequently used by accounts that blur the line between education and marketing, and the ADHD angle is a fast-growing TikTok trend where nootropic and peptide sellers have found a receptive audience of people frustrated with stimulant medications.

What does the science actually show?

NAD+ is genuinely involved in mitochondrial energy metabolism and plays a role in DNA repair via sirtuin and PARP pathways. That part is not disputed. The problem is the gap between that mechanistic role and the clinical outcomes being implied. A 2023 randomized trial by Dolopikou et al. in the European Journal of Nutrition found that NMN supplementation (an NAD+ precursor) raised blood NAD+ levels by roughly 40% over 30 days in older adults, but functional energy and fatigue improvements were modest and not dramatic. For ADHD specifically, the evidence is essentially nonexistent at the clinical trial level. Semax, a synthetic heptapeptide originally developed in Russia, has shown neuroprotective and BDNF-modulating effects in animal models, but controlled human trials for ADHD are absent from the published literature. Selank has anti-anxiety data from small Russian studies but no peer-reviewed ADHD evidence that would survive scrutiny in a Western regulatory context.

Where does the social media noise diverge from clinical reality?

The framing on TikTok typically treats NAD+ as a direct ADHD treatment, not a general metabolic support compound. That is a significant leap. ADHD is driven primarily by dopamine and norepinephrine dysregulation in prefrontal circuits. NAD+ affects mitochondrial function broadly. There is no established mechanism by which raising NAD+ levels specifically corrects the dopaminergic deficits seen in ADHD, and no clinical trial has tested this hypothesis directly. Social media creators also tend to conflate subjective energy improvements with objective attention improvements. These are not the same thing. A 2022 review by Lautrup et al. in Cell Metabolism was careful to note that NAD+ augmentation research in humans is still in early stages, with most trials underpowered and short in duration. The peptide angle adds another layer of regulatory ambiguity: semax and selank are not FDA-approved for any indication, and their compounded forms have not been evaluated in the same controlled settings as pharmaceutical stimulants used in actual ADHD treatment.

What should you actually know?

If you have ADHD and are considering NAD+ or peptide protocols as alternatives to evidence-based treatment, here is the honest summary. First-line ADHD treatments, meaning stimulant medications and certain non-stimulants, have decades of controlled trial data behind them. NAD+ precursors have plausible biological rationale but no ADHD-specific trial data. Peptides like semax and selank exist in a regulatory gray zone in the United States, are not FDA-approved, and most of what circulates about them comes from animal studies or anecdotal reports. The combination of these compounds is not tested for safety in stacked protocols. Anyone recommending a specific NAD+ dose or peptide combination for ADHD through a TikTok bio link is operating outside what the published evidence supports. That does not automatically mean the products are useless, but it does mean the certainty of the claims almost certainly exceeds the certainty of the data. Talk to a licensed clinician before acting on this kind of content.